Document ID: chunk:federal_register_of_legislation:F2023L01747:schedule:1:p30
Version: federal_register_of_legislation:F2023L01747
Segment Type: schedule
Provision Reference: sch 1 (pt 30/31)
Character Range: 102270–105796

AND
                 The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication.
                 Patient must not be undergoing retreatment (second/subsequent treatment course) with this drug where prior treatment of CLL/SLL with this same drug was unable to prevent disease progression; AND
                 Patient must be undergoing treatment through this treatment phase listing for the first time (initial treatment); OR
                 Patient must be undergoing continuing treatment through this treatment phase listing, with disease progression being absent.

     [114]           Schedule 5, entry for Adalimumab in the form Injection 40 mg in 0.4 mL pre-filled syringe [GRP-25058]
     insert in alphabetical order in the column headed "Brand": Adalicip

     [115]           Schedule 5, entry for Adalimumab in the form Injection 40 mg in 0.4 mL pre-filled pen [GRP-25060]
     insert in alphabetical order in the column headed "Brand": Adalicip

     [116]           Schedule 5, entry for Adalimumab in the form Injection 40 mg in 0.4 mL pre-filled pen [GRP-27088]
     insert in alphabetical order in the column headed "Brand": Adalicip

     [117]           Schedule 5, entry for Adalimumab in the form Injection 40 mg in 0.4 mL pre-filled syringe [GRP-27089]
     insert in alphabetical order in the column headed "Brand": Adalicip

     [118]           Schedule 5, after entry for Amoxicillin with clavulanic acid in the form Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL [GRP-28006]
     insert:
Benzathine benzylpenicillin  GRP-28213  Injection containing 1,200,000 units benzathine benzylpenicillin tetrahydrate in 2.3 mL single use pre-filled syringe  Injection  Bicillin L-A
                                        Powder for injection 1,200,000 units with diluent 5 mL (S19A)                                                          Injection  Benzylpenicillin Benzathine (Brancaster Pharma, UK)

     [119]           Schedule 5, entry for Doxycycline in the form Tablet 100 mg (as monohydrate) [GRP-14639]
     omit from the column headed "Brand": APO-Doxycycline

     [120]           Schedule 5, entry for Doxycycline in the form Tablet 100 mg (as monohydrate) [GRP-15555]
     omit from the column headed "Brand": APO-Doxycycline

     [121]           Schedule 5, entry for Doxycycline in the form Tablet 50 mg (as monohydrate) [GRP-15635]
     omit from the column headed "Brand": APO-Doxycycline

     [122]           Schedule 5, entry for Esomeprazole in the form Tablet (enteric coated) 40 mg (as magnesium trihydrate) [GRP-17061]
         (a)           omit from the column headed "Brand": Esomeprazole Apotex
         (b)           insert in alphabetical order in the column headed "Brand": Esomeprazole Viatris

     [123]           Schedule 5, entry for Esomeprazole in the form Tablet (enteric coated) 20 mg (as magnesium trihydrate) [GRP-17188]
         (a)           omit from the column headed "Brand": Esomeprazole Apotex
         (b)           insert in alphabetical order in the column headed "Brand": Esomeprazole Viatris

     [124]           Schedule 5, entry for Filgrastim in the form Injection 480 micrograms in 0.5 mL single-use pre-filled syringe [GRP-23385]
     omit from the column headed "Brand": Neupogen

     [125]           Schedule 5, after entry for Glucagon in the form Injection set containing glucagon hydrochloride 1 mg (1